Xoma enters $15M royalty monetization arrangement with Twist Bioscience

XOMA Royalty Corporation (XOMA) has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation (TWST) to acquire a 50 percent economic interest in all future milestones and royalties associated with the 60-plus partnered early-stage programs across 30 partners enabled by Twist Bioscience’s Biopharma Solutions business unit. Under the terms of the agreement, XOMA Royalty has acquired 50 percent of the economics related to Twist Bioscience’s 60-plus early-stage programs across 30 partners for a $15 million upfront payment.